SCHEMBL7528115

SCHEMBL7528115

COc1ccc(OC)c(S(=O)(=O)Nc2ccc(O)cc2)c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.72
KMT2A Q03164 3/20 0.71
MEN1 O00255 2/20 0.71
LMNA P02545 1/20 0.71
ALOX12 P18054 1/20 0.71
ALDH1A1 P00352 2/20 0.69
NPSR1 Q6W5P4 1/20 0.69
L3MBTL1 Q9Y468 2/20 0.69
TP53 P04637 3/20 0.67
ALPL P05186 3/20 0.63
POLB P06746 2/20 0.62
GAA P10253 2/20 0.62
KDM4E B2RXH2 1/20 0.62
MAPT P10636 1/20 0.62
PKM P14618 1/20 0.62
HPGD P15428 1/20 0.62
ALOX15 P16050 1/20 0.62
CASP1 P29466 1/20 0.62
HTT P42858 1/20 0.62
HSD17B10 Q99714 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530465 0.91 SMN1; SMN2 (0.79) SMN1; SMN2KMT2AMEN1LMNAALOX12
SCHEMBL7535714 0.86 SMN1; SMN2 (0.72) SMN1; SMN2KMT2AMEN1LMNAALOX12
SCHEMBL5962533 0.86 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AMEN1LMNAALOX12
SCHEMBL7529463 0.86 TP53 (0.80) SMN1; SMN2KMT2AMEN1LMNAALOX12
SCHEMBL7536903 0.86 LMNA (0.75) SMN1; SMN2KMT2AMEN1LMNAALOX12
SCHEMBL95715 0.86 SMN1; SMN2 (0.71) SMN1; SMN2KMT2AMEN1LMNAALOX12
SCHEMBL21760616 0.84 ALPL (0.62) SMN1; SMN2KMT2AMEN1LMNAALOX12
SCHEMBL7536769 0.83 SMN1; SMN2 (0.68) SMN1; SMN2KMT2AMEN1LMNAALOX12
SCHEMBL15212665 0.83 ALPL (0.87) ALPL
SCHEMBL15480531 0.83 SMN1; SMN2 (0.76) SMN1; SMN2KMT2AMEN1LMNAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020183393-A1 Inhibitors of Rho C ICONIX PHARMACEUTICALS INC. 2002-12-05 US disclosed
WO-2002022565-A1 INHIBITORS OF RHO C ICONIX PHARMACEUTICALS, INC. (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183393-A1 Inhibitors of Rho C RHOC, ROCK1, RHOA SMN1; SMN2 2961/4885KMT2A 3479/4885MEN1 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.